Skip to content
Company Analysis

MaxCyte, Inc. MXCT

A comprehensive view of key metrics, scores, and financial health for MaxCyte, Inc.

Overview of MaxCyte, Inc.

MXCT NMS
Healthcare Medical Devices Framework: Medical Devices & Diagnostics Micro Cap
MaxCyte, Inc. (MXCT), is a Micro Cap company, in the Medical Devices industry, last closed at $1.54, about 0.0% overvalued vs fair value, -0.6% 1Y return, ranked 668/1145 in sector.
Metrics Rev Growth -14.5% ROE -23.6% Gross Margin 81.2%
USD 1.54
1.99%
(Delayed)
• Vol 90d: 72.0%
52-Week Range
Market Cap
$158.94M
Enterprise Value
$143.90M
Overall Score
View breakdown
Overall
Growth
Fair
Profitability
Fair
Health
Fair
Efficiency
Fair
Valuation
Weak
Growth
Fair
Profitability
Fair
Health
Fair
Efficiency
Fair
Valuation
Weak
Completeness: 82%
Confidence: 85%
Updated: Oct 24
Top Beats
No strong beats yet

Quick Facts

Website https://www.maxcyte.com
HQ Rockville, MD
Employees 114
Fiscal year Dec 31

Next Events

Earnings Nov 10 Call: Nov 10

Fair Value Snapshot

Bear Base Bull
$0
$0
$0
Current: $1.54

Engine Room Money Flow™

Micro Cap

Medical Devices & Diagnostics - Where revenue goes and how value is created

Flow Steps
Total Revenue
$33.0M
-14.5%%
Gross Profit
$26.8M
-15%%
Operating Income (GAAP)
-$51.9M
-1.4%%
EBITDA
-$40.1M
13.5%%
Money Flow Bridge
Flow Direction: Money moves from left to right
Components: Breakdown shows composition of each stage
Industry-Specific: Medical Devices & Diagnostics

Quality & Reliability Indicators

Gross Margin
81.2%
Excellent

Gross Profit / Revenue — primary moat signal for MedTech. ≥65% indicates IP-protected consumables with strong pricing power.

Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium

Where It Leaks

Cash Flow Health healthy
Strong cash conversion with minimal leakage across profit-to-cash-to-value chain.
0
Active Leaks
0/0
Improving
0
High Impact
0
Critical
Moat Analysis Medical Devices & Diagnostics

Competitive Advantage Assessment

Evaluating MaxCyte, Inc.'s durable competitive advantages across 6 defense dimensions

Overall Moat Strength
44
/100
Developing
Scores based on quantitative metrics and qualitative factors
Full moat analysis

Key strengths

  • Elite Gross Margins Gross margin quality is top-tier vs peers (score 0.86). This signals strong consumable attach-rate economics.
  • Durable Capital Returns ROIC durability is strong (score 0.66). Consistent returns confirm the moat is not eroding.

Key risks

  • Weak FCF Generation FCF margin quality lags peers (score 0.31). Below-peer FCF conversion is a MedTech quality warning.
  • Below-Peer Operating Margin Operating margin level is below peers (score 0.31). SG&A leverage needs improvement to close the gap.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power & Consumable Moat

Moderate
71
Premium

Signals, strengths and risks for Pricing Power & Consumable Moat

Premium

Signals, strengths and risks for R&D Pipeline & Capital Returns

Premium

Signals, strengths and risks for FCF Quality & Cash Conversion

Premium

Signals, strengths and risks for Commercial Execution

Premium

Signals, strengths and risks for Capital Structure & Resilience

Premium

Signals, strengths and risks for Growth Durability

Trade-Off Ledger™

Where management spends the performance budget - Growth, Profitability, or Safety

Healthcare: MedTech (Devices & Supplies) vs Industry Peers 83% Coverage
Trade-Off Triangle Visualization A ternary plot showing MXCT's balance between Growth (20.4%), Profitability (44.4%), and Safety (35.2%). Growth 20% Safety 35% Profitability 44%

Click axes to expand details. Marker shows current allocation.

3-Year Trend Analysis Locked
Upgrade to unlock the full 3-year trend analysis and deltas.

Growth

19th percentile vs peers
20
Key Signals
Rev Growth YoY -14.5% 18p EPS Growth YoY -7.1% 27p Revenue CAGR 3Y -9.3% 15p Asset Growth YoY -15.4% 18p
Strengths
  • Gross Profit Margin in top 20% of peers (81.2%, 90th percentile)
  • Equity/Assets in top 20% of peers (84.7%, 87th percentile)
  • Conservative leverage compared to industry peers
Risks
  • Growth in bottom 20% of peers (percentile: 19)
  • Rev Growth YoY in bottom 20% of peers (-14.5%)

Profitability

43th percentile vs peers
43
Key Signals
Strengths
Risks
Premium
Unlock full Profitability drilldowns

See the signal-level drivers and insights behind this axis. Upgrade to reveal the full Trade-Off Ledger.

Upgrade Now

Safety

34th percentile vs peers
34
Key Signals
Strengths
Safety drilldowns are available to premium members.

Two Futures

Scenario-based fair value ranges for MaxCyte, Inc..

Loading valuation model...
Unable to Compute Fair Value

This company cannot be valued using standard models.

What this means: The Scenario Theatre requires financial data (revenue, cash flow, shares outstanding) to calculate fair value estimates. This data may be unavailable for:

  • Recently listed companies (IPOs, SPACs)
  • Shell companies or holding companies
  • Companies that haven't filed recent financials
  • Foreign companies with limited data coverage
X.X%
X%XX%
X.X%
-XX%XX%
XX.X%
-XX%XX%
Adjust the sliders above to explore different valuation scenarios.
Unlock Premium
Reveal the full Scenario Theatre
See live sliders, narratives, and full Bear/Base/Bull outcomes.
Upgrade Now
Bear
-
- - -
- upside
-
Base
$-0.20
- - -
- upside
Snapshot base estimate
Bull
-
- - -
- upside
-
Fair Value Range Current: $-
$- $- $-
Actions & Info
Send Feedback
Please select a category.
0/1000